Coloplast A/S

Chart & Performance

D1W1MN

P/E

37.18

P/S

7.26

EPS

21.44

Div Yield, %

2.39%

Shrs. gr., 5y

—

Rev. gr., 5y

8.29%

Revenues

27.03b

+10.33%

Net income

5.05b

+5.62%

CFO

2.77b

-34.55%

Dividend

May 13, 20245 DKK/sh

Earnings

Feb 07, 2025

Profile

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

URL

https://www.coloplast.dk/

IPO date

Jan 01, 1983

Employees

14,700

Domiciled in

Incorporated in

Valuation

Order:

Title DKK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title DKK in thousands, except ratios and share amounts	2024‑09	2023‑09	2022‑09	2021‑09	2020‑09	2019‑09	2018‑09	2017‑09	2016‑09	2015‑09
Income
Revenues	27,030,000 10.33%	24,500,000 8.51%	22,579,000 16.23%
Cost of revenue	20,480,000	17,677,000	15,718,000
Unusual Expense (Income)
NOPBT	6,550,000	6,823,000	6,861,000
NOPBT Margin	24.23%	27.85%	30.39%
Operating Taxes	1,343,000	1,242,000	1,421,000
Tax Rate	20.50%	18.20%	20.71%
NOPAT	5,207,000	5,581,000	5,440,000
Net income	5,052,000 5.62%	4,783,000 1.64%	4,706,000 -2.47%
Dividends	(4,720,000)	(4,247,000)	(4,041,000)
Dividend yield	2.40%	2.64%	2.45%
Proceeds from repurchase of equity	500,000	9,134,000	(619,000)
BB yield	-0.25%	-5.67%	0.37%
Debt
Debt current	5,338,000	7,345,000	1,853,000
Long-term debt	18,278,000	13,116,000	17,560,000
Deferred revenue		199,000
Other long-term liabilities	155,000	6,000	396,000
Net debt	22,726,000	19,446,000	18,948,000
Cash flow
Cash from operating activities	2,766,000	4,226,000	5,099,000
CAPEX	(1,346,000)	(1,241,000)	(1,135,000)
Cash from investing activities	(1,336,000)	(8,957,000)	(11,759,000)
Cash from financing activities	(1,518,000)	5,265,000	6,591,000
FCF	(9,062,000)	14,539,000	(297,000)
Balance
Cash	788,000	911,000	633,000
Long term investments	102,000	104,000	(168,000)
Excess cash
Stockholders' equity	17,942,000	14,860,000	5,602,000
Invested Capital	40,726,000	29,400,000	26,054,000
ROIC	14.85%	20.13%	29.96%
ROCE	15.16%	21.65%	24.39%
EV
Common stock shares outstanding	224,900	215,500	212,800
Price	875.00 17.04%	747.60 -3.63%	775.80 -22.92%
Market cap	196,787,500 22.15%	161,107,800 -2.41%	165,090,240 -23.07%
EV	219,513,500	181,709,800	184,533,240
EBITDA	7,840,000	7,892,000	7,791,000
EV/EBITDA	28.00	23.02	23.69
Interest	882,000	638,000	172,000
Interest/NOPBT	13.47%	9.35%	2.51%